

Cell Line Data Sheet for SK-N-BE(1)

Disease: Neuroblastoma
Phase of Therapy: Post-Chemotherapy (Progressive Disease)
Treatment:
Disease Stage: 4
Gender: Male
Age at diagnosis: 24 months
Race: N/A
Age at sample collection: N/A
Source of Culture: Bone Marrow
Primary Tumor Site: Brain
Date Established: November 1972

MYCN Patient: Amplified
MYCN Cell line: N/A
TH mRNA: Positive
p53 functionality: Functional
Telomere Mechanism: TERT+
ALK: WT

IC90 (DIMSCAN*):	<u>CBDCA (µg/ml)</u>	<u>CDDP (µg/ml)</u>	<u>DOX (ng/ml)</u>	<u>ETOP (ng/ml)</u>	<u>L-PAM (µg/ml)</u>
*see reference 4	0.2	<0.1	<0.1	158	0.8
	CBDCA, carboplatin; CDDP, cisplatin; DOX, doxorubicin; ETOP, etoposide; L-PAM, melphalan				

Growth Conditions: Please see Protocols section at <https://www.cccells.org/protocols.php>
5% CO₂, 20% O₂, 37.0°C

Media Formulation: Please see Protocols section at <https://www.cccells.org/protocols.php>
Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid)

Doubling Time: 27 hours
Growth Properties: Suspended, grow mostly in tight clumps, also a small population of attached cells

STR Profile: May be obtained at <https://strdb.cccells.org/>

Notes: The Childhood Cancer Repository has a matching direct-to-culture diagnosis cell line available from this same patient – SK-N-BE(1).

All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis.

Cell Line Data Sheet for SK-N-BE(1)

References:

1. Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, Triche TJ, Reynolds CP: Loss of p53 function confers high-level multi-drug resistance in neuroblastoma cell lines. *Cancer Res.* 61:6185-6193, 2001. PubMed ID: 11507071
<https://cancerres.aacrjournals.org/content/61/16/6185.long>
2. Reynolds CP, Brodeur GM, Tomayko MM, Donner L, Helson L, Seeger RC, Triche TJ: Biological classification of cell lines derived from human extra-cranial neural tumors. *Prog Clin Biol Res.* 271:291-306, 1988. PubMed ID: 3406003
<https://pubmed.ncbi.nlm.nih.gov/3406003/>
3. Keshelava N, Seeger RC, Groshen S, Reynolds CP: Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. *Cancer Research.* 58:5396-5405, 1998. PubMed ID: 9850071
<https://cancerres.aacrjournals.org/content/58/23/5396.long>
4. Biedler JL, Roffler-Tarlov S, Schachner M, Freedman LS: Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. *Cancer Res.* 38:3751-3757, 1978. PubMed ID: 29704
https://cancerres.aacrjournals.org/content/38/11_Part_1/3751.long
5. Keshelava N, Groshen S, Reynolds CP. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. *Cancer Chemoth Pharm.* 45: 1-8, 2000. PubMed ID: 10647494
<https://link.springer.com/article/10.1007%2FPL00006736>
6. Thompson PM, Maris JM, Hogarty MD, Seeger RC, Reynolds CP, Brodeur GM, White PS. Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at Other Tumor Suppressor Loci in Neuroblastoma. *Cancer Res.* 61, 679-686, 2001. PubMed ID: 11212268
<https://cancerres.aacrjournals.org/content/61/2/679.long>
7. Kang MH, Smith MA, Morton CL, Keshlava N, Houghton PJ, Reynolds CP. National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing. *Pediatr Blood Cancer.* 56: 239-249, 2011. PubMed ID: 20922763
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005554/>



Cell Line Data Sheet for SK-N-BE(1)

Cell Line Name: SK-N-BE(1)

Low confluency (10x magnification)

High confluency (10x magnification)

Low confluency (20x magnification)

High confluency (20x magnification)